Olumiant (baricitinib) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 16 Diseases   90 Trials   90 Trials   5359 News 
139 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olumiant (baricitinib) / Eli Lilly
2017-001977-18: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
26
Europe
Micardis, Jardiance, Trajenta, Olumiant
University Medical Center Groningen, University Medical Center Groningen
Type 2 diabetes and albuminuria, Type 2 diabetes and albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2018-004558-30: Synovial ultrasound as primary outcome in a 3-arm, randomized, open-label, parallel active controlled, multicenter international study comparing baricitinib, alone and combined with MTX versus TNF-alfa inhibitor in rheumatoid arthritis patients: Searching for synovium predictors of response. Ultrasonido sinovial como resultado principal en un estudio internacional, multicéntrico, aleatorizado, abierto de 3 brazos, con control activo de grupos paralelos, comparando baricitinib solo y combinado con metotrexato frente a un inhibidor TNF-α en pacientes con artritis reumatoide: Buscando predictores sinoviales de respuesta.

Not yet recruiting
4
186
Europe
Olumiant, Enbrel, Metotrexato, Coated tablet, Powder and solvent for solution for injection, Olumiant, Enbrel
Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Lilly S.A., Spain
rheumatoid arthritis Artritis reumatoide, rheumatoid arthritis Artritis reumatoide, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2019-004359-35: Induction of Cure in Early Arthritis

Not yet recruiting
4
309
Europe
Tablet, Olumiant
Leiden University Medical Center, Eli Lilly
early unclassified arthritis, Joint inflammation with unknown cause, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2020-005773-27: BARIcitinib Cognitive Emotional and Neural signaTuREBARICENTRE BARIcitinib signaTuRE Cognitive, Emotionnelle et NeuronaleBARICENTRE

Not yet recruiting
4
80
Europe
Baricitinib, LY3009104, Tablet, OLUMIANT 4 mg, OLUMIANT 4mg
ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP), DGOS
Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist Patients atteints de polyarthrite rhumatoïde et indication d'un traitement par baricitinib selon un rhumatologue, Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist Patients atteints de polyarthrite rhumatoïde et indication d'un traitement par baricitinib selon un rhumatologue, Diseases [C] - Symptoms and general pathology [C23]
 
 
2021-001661-21: Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot Study

Not yet recruiting
4
20
Europe
Tablet, Injection, Forxiga, Jardiance, Ozempic, Telmisartan, Losartan, hydrochlorthiazide, Spironolactone, Trental, Olumiant, Kerendia, Rybelsus
Herlev and Gentofte Hospital, Herlev and Gentofte Hospital
Diabetic Kidney Disease, Kidney Disease due to diabetes mellitus type 2, Diseases [C] - Hormonal diseases [C19]
 
 
NCT05300932: A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Recruiting
4
60
RoW
Baricitinib, Olumiant, Cyclophosphamide, Cytoxan
Tongji Hospital
Systemic Sclerosis
03/23
04/23
2019-000505-72: Baricitinib in patients suffering from Rheumatoid Arthritis

Not yet recruiting
4
200
Europe
baricitinib, Film-coated tablet, Olumiant
Transparency in Healthcare, Transparency in Healthcare, Eli Lilly
Pragmatic trial baricitinib versus First biological in “Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT), Baricitinib in the treatment of patients suffering from Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
DermAtOmics-II, NCT06366932: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Recruiting
4
150
Europe
Second-line systemic treatment, Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib, Folllow-up of second-line systemic treatment already started
Instituto de Investigación Hospital Universitario La Paz
Atopic Dermatitis
09/25
09/25
NCT05660655: Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

Completed
4
94
RoW
Baricitinib 4 MG Oral Tablet, for group B, Baricitinib 2 MG, for group A
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Rheumatoid Arthritis
09/23
09/23
COVER, NCT05080218: COVID-19 VaccinE Response in Rheumatology Patients

Completed
4
841
US
Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz
Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
04/24
05/24
NCT05827497: Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial

Recruiting
4
132
RoW
Baricitinib 2 MG, Baricitinib 2mg, Methotrexate 25mg
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Rheumatoid Arthritis
03/24
03/24
NCT06240351: A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Recruiting
4
15
US
Baricitinib 4 MG Oral Tablet, Olumiant
University of Alabama at Birmingham, Eli Lilly and Company
Frontal Fibrosing Alopecia
07/26
07/27
ChiCTR2300069207: Clinical study of the efficacy and safety of baricitinib in the treatment of chronic tophi arthritis

Recruiting
4
20
 
Baricitinib 2mg/day with basic therapy ;Placebo with basic therapy
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Self-funded
chronic tophi arthritis
 
 
BARICENTRE, NCT05238896: BARIcitinib Cognitive Emotional and Neural signaTuRE

Terminated
4
5
Europe
Baricitinib Oral Tablet [Olumiant], Baricitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
02/23
03/23
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/26
04/26
JAK-TAP, NCT06687551: JAK Inhibitor Dose TAPering Strategy Study

Not yet recruiting
4
308
NA
Baricitinib (LY3009104) 4 mg, filgotinib 200mg/day, Tofacitinib 5 mg twice daily, Upadacitinib 15 MG
University Hospital, Toulouse
Rhumatoid Arthisis
04/29
04/29
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

Recruiting
4
286
Europe
Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
University Hospital, Strasbourg, France
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
03/29
03/29
RA-BRIDGE, NCT03915964 / 2018-003351-37: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Active, not recruiting
4
2600
Europe, US, RoW
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/25
02/26
NCT05955066: Effect of JAK Inhibitor on Erosion Healing in RA

Recruiting
4
60
RoW
Baricitinib 4 MG, Olumiant, Placebo
Chinese University of Hong Kong
Rheumatoid Arthritis
02/26
06/26
ChiCTR2400081010: A multicenter observational clinical study of the difference in efficacy of baricitinib monotherapy and combination therapy and its effect on inflammatory markers in patients with moderate-to-severe active rheumatoid arthritis

Not yet recruiting
4
300
 
None
The University of Hong Kong-Shenzhen Hospital; The University of Hong Kong-Shenzhen Hospital, None
Rheumatoid arthritis
 
 
2016-004675-52: A Study of Baricitinib (LY3009104) in Participants With Active Psoriatic Arthritis

Ongoing
3
622
Europe
Olumiant, LY3009104, Film-coated tablet, Olumiant
Eli Lilly and Company, Lilly S.A., ELI LILLY & COMPANY, LILLY CORPORATE CENTER, Eli Lilly and Company
Active Psoriatic Arthritis, Psoriatic Arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

Checkmark Safety and efficacy data from BREEZE-AD4 study in patients with moderate to severe atopic dermatitis
Jan 2020 - Jan 2020:  Safety and efficacy data from BREEZE-AD4 study in patients with moderate to severe atopic dermatitis
Completed
3
463
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo, Topical corticosteroid
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
11/19
04/23
2020-001052-18: A Multicentre, Adaptive, Randomised, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults

Ongoing
3
800
Europe, RoW
Remdesivir, Not applicable, Infusion, Olumiant
Regents of the University of Minnesota, National Institute of Health, University of Minnesota, University of Minnesota, USA
COVID-19 (Coronavirus RNA), COVID-19 (A respiratory disease caused by a novel coronavirus), Health Care [N] - Environment and Public Health [N06]
 
 
BREEZE-AD3, NCT03334435 / 2017-000873-35: A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Completed
3
1645
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
09/20
07/23
BRAVE-AA2, NCT03899259: A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA2 trial for in adults with severe alopecia areata
Mar 2021 - Mar 2021: Efficacy and safety data from BRAVE-AA2 trial for in adults with severe alopecia areata
Completed
3
546
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
01/21
11/24
NCT04693026: Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Recruiting
3
150
RoW
Remdesivir, Ninavir, Baricitinib, Tocilizumab
M Abdur Rahim Medical College and Hospital, First affiliated Hospital Xi'an Jiaoting University
Covid19, Covid-19 ARDS
02/21
03/21
2020-004987-24: Baricitinib in patients with relapsing or naïve dermatomyositis Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs

Not yet recruiting
3
62
Europe
Baricitinib, Tablet, OLUMIANT 4mg
Assistance Publique-Hopitaux de Paris, ministere de la santé
Baricitinib in patients with relapsing or naïve dermatomyositis.Multicenter trial, double blind randomized controlled trial with 2 parallel groups. This is an add-on trial with intention to treat analysis. Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs. Essai contrôlé randomisé en double aveugle multicentrique avec 2 groupes parallèles. Il s'agit d'un essai en add-on en intention de traiter, Baricitinib in patients with relapsing or naïve dermatomyositis Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs, Body processes [G] - Immune system processes [G12]
 
 
2020-004345-37: Combination of baricitinib and adalimumab vs. baricitinib alone in patients with rheumatoid arthritis Efficacité et tolerance de la combinaison baricitinib /adalimumab vs. baricitinib seul dans le traitement de la polyarthrite rhumatoïde

Not yet recruiting
3
178
Europe
Prednisone, Cachet, Injection, OLUMIANT 4mg, IMRALDI 40mg, Prednisone
CHU de Bordeaux, Ministère de la Santé
rheumatoid arthritis (RA) polyarthrite rhumatoïde (PR), rheumatoid arthritis (RA) polyarthrite rhumatoïde (PR), Body processes [G] - Immune system processes [G12]
 
 
2020-005081-34: A randomized study to evaluate the efficacy and Safety of Baricitinib to induce Remission and to spare Glucocorticoids in subjects with new-onset Polymyalgia Rheumatica. Eine randomisierte Studie zur Beurteilung der Wirksamkeit und Sicherheit von Baricitinib zur Remissionsinduktion und als Glukokortikoid sparender Wirkstoff in Patienten mit früher Polymyalgia rheumatica

Ongoing
3
18
Europe
Olumiant, LY3009104, Film-coated tablet, Olumiant
Medical University of Vienna, Medical University of Vienna
Polymyalgia rheumatica (PMR), Polymyalgia rheumatica (PMR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-001338-21: A Study of Baricitinib in Children With COVID-19 (COV-BARRIER-PEDS)

Ongoing
3
24
Europe
Olumiant, LY3009104, Oral suspension
Eli Lilly and Company, Eli Lilly and Company
COVID-19 infection, COVID-19 infection, Diseases [C] - Virus Diseases [C02]
 
 
BAREBONE, NCT03701789: Effect of Baricitinib Treatment on Peripheral Bone in RA

Active, not recruiting
3
15
Europe
Baricitinib, Oliumiant
University of Erlangen-Nürnberg Medical School
Rheumatoid Arthritis, Bone Density, Finger Joints
10/21
10/21
NCT04890626: Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

Completed
3
356
Europe
Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA], Baricitinib + dexamethasone, Dexamethasone
Instituto de Investigación Hospital Universitario La Paz
SARS-CoV-2 Infection
07/23
07/23
NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

Withdrawn
3
382
RoW
Baricitinib, Janus kinase inhibitors, Dexamethasone, Steroids, Remdesivir, Anti-viral
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
COVID-19 Pneumonia
12/21
12/21
AMMURAVID, NCT04832880 / 2020-001854-23: Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the Trial)

Not yet recruiting
3
4000
Europe
Baricitinib Oral Tablet [Olumiant], Olumiant, Remdesivir, Veklury, Dexamethasone
ASST Fatebenefratelli Sacco, AIFA
Covid19
03/22
12/22
NCT05056558: Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

Not yet recruiting
3
480
RoW
Baricitinib, Baricent, Placebo, Given Orally
Incepta Pharmaceuticals Ltd
Covid19
04/22
09/22
BREEZE-AD-PEDS, NCT03952559 / 2018-000349-38: A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Active, not recruiting
3
516
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo, Topical corticosteroid
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
04/22
05/26
2022-000366-18: Efficacy and Tolerance of Baricitinib, a JAK inhibitor, in the treatment of refractory non-infectious uveitis Efficacité et Tolérance du Baricitinib, un inhibiteur de JAK, dans le traitement des uvéites non-infectieuses non-antérieures réfractaires

Not yet recruiting
3
33
Europe
Tablet, OLUMIANT
CHU de ROUEN, CHU de Rouen
Active non-anterior non-infectious uveitis, Active non-anterior non-infectious uveitis, Diseases [C] - Eye Diseases [C11]
 
 
NCT04088409 / 2019-000119-10: A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Active, not recruiting
3
30
Europe
Baricitinib, LY3009104, Adalimumab
Eli Lilly and Company
Uveitis
07/23
07/28
JAKUVEITE, NCT05651880: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Not yet recruiting
3
33
NA
Baricitinib 4 MG
University Hospital, Rouen
Active Non-anterior Non-infectious Uveitis
08/23
08/26
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
10/23
04/24
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
BardSSc, NCT06936215: Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Recruiting
3
24
RoW
tab baricitinib 4 mg daily, tab methotrexate 25 mg weekly with folic acid 5 mg weekly
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Diffuse Cutaneous Systemic Sclerosis
05/25
05/25
REVERSE-LC, NCT05858515: REVERSE-Long COVID-19 With Baricitinib Study

Withdrawn
3
550
US
Baricitinib 4 MG, Olumiant, Placebo
Vanderbilt University Medical Center, Emory University, University of California, San Francisco, University of Minnesota, Vanderbilt University, Yale University
Post-Acute COVID-19 Syndrome
12/27
12/29
COV-BARRIER, NCT05074420 / 2021-001338-21: A Study of Baricitinib (LY3009104) in Children With COVID-19

Recruiting
3
24
Europe, US, RoW
Baricitinib, LY3009104
Eli Lilly and Company, Eli Lilly and Company
Covid19, Corona Virus Infection
04/26
05/26
REVERSE-LC, NCT06631287: Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Recruiting
3
550
US
Baricitinib, OLUMIANT, Placebo
Wes Ely, National Institutes of Health (NIH), National Institute on Aging (NIA)
Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
11/26
07/27
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/27
08/29
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, anti-TNF therapy, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/26
12/26
TREAT-HAP, NCT05914584: "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Not yet recruiting
3
450
Europe
Baricitinib 4 MG
Nantes University Hospital
Hospital-acquired Pneumonia
08/25
12/25
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BIRD, NCT04972760: Baricitinib in Patients With Relapsing or naïve Dermatomyositis

Recruiting
3
62
Europe
Baricitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Dermatomyositis
02/26
02/26
PALETTE, NCT06381661: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial

Not yet recruiting
3
2000
NA
Tocilizumab, Baricitinib, Anakinra, Hydrocortisone, Hydrocortisone and fludrocortisone, Heparin, Low molecular weight heparin, Recombinant humanThrombomodulin( rhTM), Sivelestat, Fresh frozen plasma, Usual care
Assistance Publique - Hôpitaux de Paris
Sepsis
05/29
04/32
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
02/27
12/28
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Checkmark From BRAVE-AA1 trial for alopecia areata
Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata
Completed
2/3
784
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
02/21
01/25
NCT04517253 / 2025-000001-16: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Terminated
2/3
10
Japan
Baricitinib, LY3009104
Eli Lilly and Company, Eli Lilly and Company
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
10/21
11/24
NCT04891133 / 2021-000541-41 / ACTRN12619000823178: EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

Terminated
2/3
290
Europe, RoW
Baricitinib, Olumiant, Placebo
Oslo University Hospital, Institut National de la Santé Et de la Recherche Médicale, France, Epidemiological and Clinical Research Information Network
Stroke, Memory deficits
12/22
01/23
NCT05686746: Use of Baricitenib to Maintain of Remission

Recruiting
2/3
80
RoW
Baricitinib 4 MG, Baricitinib 2 MG, MMF
Assiut University
Lupus or SLE, Nephritis
06/23
08/23
NCT06475820: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Active, not recruiting
2/3
150
RoW
Baricitinib, Vedolizumab, Abatacept, Cyclophosphamide
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
07/24
04/27
NCT06768840: Vitiligo, New Treatment and Serum s100B

Recruiting
2/3
50
RoW
Baricitinib, oral mini pulse, Narrow Band UVB Treatment
South Valley University
Vitiligo, Generalized
08/25
10/25
2025-000001-16: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/​CANDLE, SAVI, and AGS

Not yet recruiting
2/3
10
Japan
Olumiant, LY3009104, Film-coated tablet, Oral suspension, Olumiant
Eli Lilly and Company, Eli Lilly and Company
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Syndrome, Autoinflammatory diseases, Diseases [C] - Immune System Diseases [C20]
 
 
MYOJAK, NCT04208464 / 2019-003868-42: JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Completed
2a
15
Europe
Baricitinib
University of Manchester, Eli Lilly and Company, Clinical Trials Unit, Manchester, Karolinska Institutet
Idiopathic Inflammatory Myopathies
09/23
09/23
2015-003424-31: Treatment of autoinflammatory diseases

Not yet recruiting
2
60
Europe
Baricitinib, LY3009104, Coated tablet
Eli Lilly and Company, Eli Lilly and Company
CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome, CANDLE, SAVI, JDM, AGS, Diseases [C] - Immune System Diseases [C20]
 
 
2018-002655-14: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR study)

Not yet recruiting
2
34
Europe
OLUMIANT, Tablet, baricitinib
CHRU BREST
polymyalgia rheumatica, Inflammatory disease in the elderly, Diseases [C] - Immune System Diseases [C20]
 
 
2019-003868-42: A trial of the drug Baricitinib in the treatment of patients with muscle inflammatory conditions.

Not yet recruiting
2
25
Europe
Olumiant, Tablet, Olumiant
University of Manchester, Eli Lilly and Company
Idiopathic Inflammatory Myopathy (IIM), Inflammation of muscle tissue which can lead to profound weakness, fatigue and disability, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2020-005079-12: Efficacy and tolerability of the combination of baricitinib (4 mg) and phototherapy compared to phototherapy in adults with vitiligo-progressive disease Efficacité et tolérance de l’association du baricitinib (4 mg) et de la photothérapie par rapport à la photothérapie chez les adultes atteints de vitiligo progressif

Not yet recruiting
2
48
Europe
Baricitinib, LY3009104, Film-coated tablet, Olumiant
Centre Hospitalier Universitaire de Bordeaux, LILLY France
progressive vitiligo vitiligo progressif, progressive vitiligo vitiligo progressif, Diseases [C] - Immune System Diseases [C20]
 
 
Covid-19HUF, NCT04346147 / 2020-001321-31: Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Active, not recruiting
2
168
Europe
Imatinib tablets, Arm A, Baricitinib Oral Tablet, Arm B, Supportive tratment, Best care
Hospital Universitario de Fuenlabrada, Centro Nacional de Investigaciones Oncologicas CARLOS III
COVID-19 Pneumonia
06/21
09/21
ACTRN12620000239965: Effect of Baricitinib on Insulin Production in Type 1 Diabetes

Active, not recruiting
2
91
 
St Vincent’s Institute of Medical Research, Juvenile Diabetes Research Foundation (JDRF) International, JDRF Australia
Type 1 Diabetes Mellitus
 
 
2021-006562-20: Inhibition of JAK Enzymes in early stage Joint inflammation Hemmung der JAK-Enzyme bei frühen Formen von Gelenkentzündung

Not yet recruiting
2
20
Europe
Baricitinib blinded, Film-coated tablet, Olumiant 2 mg/4 mg Filmtabletten
Universitätsklinikum Erlangen, Lilly Deutschland GmbH
Preclinical Phase of rheumatoid arthritis Vorstadium der rheumatoiden Arthritis, Preclinical Phase of rheumatoid arthritis Vorstadium der rheumatoiden Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
BANDIT, NCT04774224: Baricitinib in New-onset Type 1 Diabetes

Completed
2
91
RoW
Baricitinib, Placebo
St Vincent's Institute of Medical Research, Juvenile Diabetes Research Foundation Australia, Juvenile Diabetes Research Foundation
Type 1 Diabetes
01/23
05/24
NCT05400889: Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Recruiting
2
10
RoW
tofacitinib, Baricitinib
Peking University People's Hospital
Idiopathic Inflammatory Myopathies
03/23
06/23
NCT05361109: Baricitinib for Cutaneous Dermatomyositis

Withdrawn
2
10
US
Baricitinib, Olumiant
University of Washington
Dermatomyositis
03/23
03/23
NCT06662721: Baricitinib for Refractory Takayasu Arteritis

Completed
2
10
RoW
Baricitinib 4 MG
Liu Tian
Takayasu Arteritis
12/23
06/24
BARVIT, NCT04822584: Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Completed
2
49
Europe
Baricitinib Oral Product, Placebo
University Hospital, Bordeaux
Vitiligo
04/23
04/23
NCT05188521: Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Completed
2
12
US
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Aaron R. Mangold
Cutaneous Lichen Planus
05/23
05/23
BACHELOR, NCT04027101: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica

Completed
2
34
Europe
Baricitinib, Placebos
University Hospital, Brest, Eli Lilly and Company
Polymyalgia Rheumatic (PMR)
08/23
08/23
BAITP, NCT05446831: Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
35
RoW
Baricitinib
Peking University People's Hospital
ITP, Immune Thrombocytopenia
06/23
12/23
NCT05263505: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Terminated
2
2
US
Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
Washington University School of Medicine, Eli Lilly and Company
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
09/23
09/23
NCT03755466: Examination of Efficacy and Safety of Baricitinib in RA Patients

Recruiting
2
90
Japan
"Baricitinib", "olumiant®", "Biologics", Tofacitinib 5 MG [Xeljanz]
Shinshu University
Rheumatoid Arthritis
11/23
11/25
NCT06158113: Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

Recruiting
2
10
US
Baricitinib 4 milligram Oral Tablet, Olumiant
University of North Carolina, Chapel Hill, Eli Lilly and Company
Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
03/25
03/25
NCT06114407: Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Recruiting
2
184
RoW
Baricitinib 2mg, Baritinib 2 mg, Tofacitinib 5 mg, Tofacent 5 mg
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Healthcare Pharmaceuticals
Spondyloarthritis, Axial
06/24
12/24
NCT04321993: Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

Active, not recruiting
2
363
Canada
Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor), Remdesivir (antiviral), Tocilizumab (interleukin 6 inhibitor)
Lisa Barrett, Nova Scotia Health Authority, Dalhousie University
COVID-19
04/24
04/24
NCT05932524: Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia

Recruiting
2
132
RoW
Baricitinib 2 MG, Olumiant, Dexamethasone, HD-DXM
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
06/24
06/25
ChiCTR2100048030: Efficacy and Safety of Baricitinib in refractory Non-infectious Uveitis

Recruiting
2
30
 
Baricitinib
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Academy Foundation of Tongji Hospital
Non-infectious Uveitis
 
 
NCT05016297: Efficacy and Safety of Baricitinib in Sjogren's Syndrome

Completed
2
90
RoW
Baricitinib, Hydroxychloroquine
Peking Union Medical College Hospital, Eli Lilly and Company
Sjogren's Syndrome
08/24
11/24
BLISS, NCT06439615: Baricitinib for the Lung Injury Following Spontaneous SAH

Not yet recruiting
2
100
NA
Baricitinib 4 MG, JAK Inhibitor, Standard treatment
Tang-Du Hospital
Spontaneous Subarachnoid Hemorrhage
12/26
06/27
JAKIH, NCT06490757: A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

Not yet recruiting
2
25
NA
Baricitinib, fluorodésoxyglucose (18F)- Positron Emission Tomography (PET)
Assistance Publique - Hôpitaux de Paris
Inflammatory Hepatocellular Adenoma
09/28
09/28
NCT05852847: Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
216
RoW
Baricitinib 2 MG [Olumiant], Olumiant, Danazol
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
11/24
05/25
NCT06849908: Baricitinib in the Treatment of Intestinal Behçet's Syndrome

Recruiting
2
56
RoW
Baricitinib, Olumiant®, Adalimumab, Humira®
Peking Union Medical College Hospital
Behcet Syndrome, Intestinal Type
06/27
06/28
NCT04901325: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Completed
2
5
US
Baricitinib, Olumiant
Oregon Health and Science University
Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
01/25
05/25
BAPTIST, NCT06768294: Baricitinib in CPPD - the Study

Not yet recruiting
2
32
Europe
Baricitinib 4 MG Oral Tablet, Methylprednisolone (Corticosteroid), Colchicine 1 MG Oral Tablet, Hydroxychloroquine 200 mg, Methotrexate + Folic Acid
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
06/26
01/27
BRIGHT, NCT06737705: Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage

Recruiting
2
100
RoW
Baritinib
De-zhi Kang, Fujian Medical University, Tianjin Medical University General Hospital
Intracerebral Hemorrhage, Acute Lung Injury(ALI)
12/25
03/26
MQ7422, NCT06797310: Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study

Not yet recruiting
2
30
RoW
Baricitinib
National Taiwan University Hospital, Eli Lilly and Company
Alopecia Areata
12/25
12/26
NCT06868381: A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Not yet recruiting
2
10
US
Baricitinib (LY3009104) 4 mg
Stanford University, Eli Lilly and Company
Cardiac Sarcoidosis
01/28
04/28
NCT06923072: Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

Recruiting
2
12
US
Baricitinib
National Heart, Lung, and Blood Institute (NHLBI)
Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
12/30
12/30
NCT03921554: JAK Inhibitor Treatment in AGS

Completed
2
54
US
Baricitinib, Olumiant
Adeline Vanderver, MD, Eli Lilly and Company
Aicardi Goutieres Syndrome
01/24
03/24
WP3, NCT05897372: Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

Terminated
2
1
Europe
ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Iain Bressendorff
Diabetic Kidney Disease
09/24
09/24
NCT06065046: Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Not yet recruiting
2
100
RoW
Baricitinib 4 MG, Baricitinib, Standard treatment, Blank control
Tang-Du Hospital
Traumatic Brain Injury
07/25
12/25
NCT05852171: Baricitinib in Idiopathic Granulomatous Mastitis

Active, not recruiting
2
20
RoW
Baricitinib, Olumiant, Baricinix
First Affiliated Hospital of Zhejiang University
Mastitis Chronic, Idiopathic Granulomatous Mastitis
04/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olumiant (baricitinib) / Eli Lilly
2017-001977-18: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
26
Europe
Micardis, Jardiance, Trajenta, Olumiant
University Medical Center Groningen, University Medical Center Groningen
Type 2 diabetes and albuminuria, Type 2 diabetes and albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2018-004558-30: Synovial ultrasound as primary outcome in a 3-arm, randomized, open-label, parallel active controlled, multicenter international study comparing baricitinib, alone and combined with MTX versus TNF-alfa inhibitor in rheumatoid arthritis patients: Searching for synovium predictors of response. Ultrasonido sinovial como resultado principal en un estudio internacional, multicéntrico, aleatorizado, abierto de 3 brazos, con control activo de grupos paralelos, comparando baricitinib solo y combinado con metotrexato frente a un inhibidor TNF-α en pacientes con artritis reumatoide: Buscando predictores sinoviales de respuesta.

Not yet recruiting
4
186
Europe
Olumiant, Enbrel, Metotrexato, Coated tablet, Powder and solvent for solution for injection, Olumiant, Enbrel
Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Lilly S.A., Spain
rheumatoid arthritis Artritis reumatoide, rheumatoid arthritis Artritis reumatoide, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2019-004359-35: Induction of Cure in Early Arthritis

Not yet recruiting
4
309
Europe
Tablet, Olumiant
Leiden University Medical Center, Eli Lilly
early unclassified arthritis, Joint inflammation with unknown cause, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2020-005773-27: BARIcitinib Cognitive Emotional and Neural signaTuREBARICENTRE BARIcitinib signaTuRE Cognitive, Emotionnelle et NeuronaleBARICENTRE

Not yet recruiting
4
80
Europe
Baricitinib, LY3009104, Tablet, OLUMIANT 4 mg, OLUMIANT 4mg
ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP), DGOS
Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist Patients atteints de polyarthrite rhumatoïde et indication d'un traitement par baricitinib selon un rhumatologue, Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist Patients atteints de polyarthrite rhumatoïde et indication d'un traitement par baricitinib selon un rhumatologue, Diseases [C] - Symptoms and general pathology [C23]
 
 
2021-001661-21: Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot Study

Not yet recruiting
4
20
Europe
Tablet, Injection, Forxiga, Jardiance, Ozempic, Telmisartan, Losartan, hydrochlorthiazide, Spironolactone, Trental, Olumiant, Kerendia, Rybelsus
Herlev and Gentofte Hospital, Herlev and Gentofte Hospital
Diabetic Kidney Disease, Kidney Disease due to diabetes mellitus type 2, Diseases [C] - Hormonal diseases [C19]
 
 
NCT05300932: A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Recruiting
4
60
RoW
Baricitinib, Olumiant, Cyclophosphamide, Cytoxan
Tongji Hospital
Systemic Sclerosis
03/23
04/23
2019-000505-72: Baricitinib in patients suffering from Rheumatoid Arthritis

Not yet recruiting
4
200
Europe
baricitinib, Film-coated tablet, Olumiant
Transparency in Healthcare, Transparency in Healthcare, Eli Lilly
Pragmatic trial baricitinib versus First biological in “Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT), Baricitinib in the treatment of patients suffering from Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
DermAtOmics-II, NCT06366932: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Recruiting
4
150
Europe
Second-line systemic treatment, Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib, Folllow-up of second-line systemic treatment already started
Instituto de Investigación Hospital Universitario La Paz
Atopic Dermatitis
09/25
09/25
NCT05660655: Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

Completed
4
94
RoW
Baricitinib 4 MG Oral Tablet, for group B, Baricitinib 2 MG, for group A
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Rheumatoid Arthritis
09/23
09/23
COVER, NCT05080218: COVID-19 VaccinE Response in Rheumatology Patients

Completed
4
841
US
Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz
Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
04/24
05/24
NCT05827497: Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial

Recruiting
4
132
RoW
Baricitinib 2 MG, Baricitinib 2mg, Methotrexate 25mg
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Rheumatoid Arthritis
03/24
03/24
NCT06240351: A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Recruiting
4
15
US
Baricitinib 4 MG Oral Tablet, Olumiant
University of Alabama at Birmingham, Eli Lilly and Company
Frontal Fibrosing Alopecia
07/26
07/27
ChiCTR2300069207: Clinical study of the efficacy and safety of baricitinib in the treatment of chronic tophi arthritis

Recruiting
4
20
 
Baricitinib 2mg/day with basic therapy ;Placebo with basic therapy
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Self-funded
chronic tophi arthritis
 
 
BARICENTRE, NCT05238896: BARIcitinib Cognitive Emotional and Neural signaTuRE

Terminated
4
5
Europe
Baricitinib Oral Tablet [Olumiant], Baricitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
02/23
03/23
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/26
04/26
JAK-TAP, NCT06687551: JAK Inhibitor Dose TAPering Strategy Study

Not yet recruiting
4
308
NA
Baricitinib (LY3009104) 4 mg, filgotinib 200mg/day, Tofacitinib 5 mg twice daily, Upadacitinib 15 MG
University Hospital, Toulouse
Rhumatoid Arthisis
04/29
04/29
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

Recruiting
4
286
Europe
Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
University Hospital, Strasbourg, France
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
03/29
03/29
RA-BRIDGE, NCT03915964 / 2018-003351-37: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Active, not recruiting
4
2600
Europe, US, RoW
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/25
02/26
NCT05955066: Effect of JAK Inhibitor on Erosion Healing in RA

Recruiting
4
60
RoW
Baricitinib 4 MG, Olumiant, Placebo
Chinese University of Hong Kong
Rheumatoid Arthritis
02/26
06/26
ChiCTR2400081010: A multicenter observational clinical study of the difference in efficacy of baricitinib monotherapy and combination therapy and its effect on inflammatory markers in patients with moderate-to-severe active rheumatoid arthritis

Not yet recruiting
4
300
 
None
The University of Hong Kong-Shenzhen Hospital; The University of Hong Kong-Shenzhen Hospital, None
Rheumatoid arthritis
 
 
2016-004675-52: A Study of Baricitinib (LY3009104) in Participants With Active Psoriatic Arthritis

Ongoing
3
622
Europe
Olumiant, LY3009104, Film-coated tablet, Olumiant
Eli Lilly and Company, Lilly S.A., ELI LILLY & COMPANY, LILLY CORPORATE CENTER, Eli Lilly and Company
Active Psoriatic Arthritis, Psoriatic Arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

Checkmark Safety and efficacy data from BREEZE-AD4 study in patients with moderate to severe atopic dermatitis
Jan 2020 - Jan 2020:  Safety and efficacy data from BREEZE-AD4 study in patients with moderate to severe atopic dermatitis
Completed
3
463
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo, Topical corticosteroid
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
11/19
04/23
2020-001052-18: A Multicentre, Adaptive, Randomised, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults

Ongoing
3
800
Europe, RoW
Remdesivir, Not applicable, Infusion, Olumiant
Regents of the University of Minnesota, National Institute of Health, University of Minnesota, University of Minnesota, USA
COVID-19 (Coronavirus RNA), COVID-19 (A respiratory disease caused by a novel coronavirus), Health Care [N] - Environment and Public Health [N06]
 
 
BREEZE-AD3, NCT03334435 / 2017-000873-35: A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Completed
3
1645
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
09/20
07/23
BRAVE-AA2, NCT03899259: A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA2 trial for in adults with severe alopecia areata
Mar 2021 - Mar 2021: Efficacy and safety data from BRAVE-AA2 trial for in adults with severe alopecia areata
Completed
3
546
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
01/21
11/24
NCT04693026: Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Recruiting
3
150
RoW
Remdesivir, Ninavir, Baricitinib, Tocilizumab
M Abdur Rahim Medical College and Hospital, First affiliated Hospital Xi'an Jiaoting University
Covid19, Covid-19 ARDS
02/21
03/21
2020-004987-24: Baricitinib in patients with relapsing or naïve dermatomyositis Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs

Not yet recruiting
3
62
Europe
Baricitinib, Tablet, OLUMIANT 4mg
Assistance Publique-Hopitaux de Paris, ministere de la santé
Baricitinib in patients with relapsing or naïve dermatomyositis.Multicenter trial, double blind randomized controlled trial with 2 parallel groups. This is an add-on trial with intention to treat analysis. Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs. Essai contrôlé randomisé en double aveugle multicentrique avec 2 groupes parallèles. Il s'agit d'un essai en add-on en intention de traiter, Baricitinib in patients with relapsing or naïve dermatomyositis Baricitinib au cours de la dermatomyosite chez des patients réfractaires ou naïfs, Body processes [G] - Immune system processes [G12]
 
 
2020-004345-37: Combination of baricitinib and adalimumab vs. baricitinib alone in patients with rheumatoid arthritis Efficacité et tolerance de la combinaison baricitinib /adalimumab vs. baricitinib seul dans le traitement de la polyarthrite rhumatoïde

Not yet recruiting
3
178
Europe
Prednisone, Cachet, Injection, OLUMIANT 4mg, IMRALDI 40mg, Prednisone
CHU de Bordeaux, Ministère de la Santé
rheumatoid arthritis (RA) polyarthrite rhumatoïde (PR), rheumatoid arthritis (RA) polyarthrite rhumatoïde (PR), Body processes [G] - Immune system processes [G12]
 
 
2020-005081-34: A randomized study to evaluate the efficacy and Safety of Baricitinib to induce Remission and to spare Glucocorticoids in subjects with new-onset Polymyalgia Rheumatica. Eine randomisierte Studie zur Beurteilung der Wirksamkeit und Sicherheit von Baricitinib zur Remissionsinduktion und als Glukokortikoid sparender Wirkstoff in Patienten mit früher Polymyalgia rheumatica

Ongoing
3
18
Europe
Olumiant, LY3009104, Film-coated tablet, Olumiant
Medical University of Vienna, Medical University of Vienna
Polymyalgia rheumatica (PMR), Polymyalgia rheumatica (PMR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-001338-21: A Study of Baricitinib in Children With COVID-19 (COV-BARRIER-PEDS)

Ongoing
3
24
Europe
Olumiant, LY3009104, Oral suspension
Eli Lilly and Company, Eli Lilly and Company
COVID-19 infection, COVID-19 infection, Diseases [C] - Virus Diseases [C02]
 
 
BAREBONE, NCT03701789: Effect of Baricitinib Treatment on Peripheral Bone in RA

Active, not recruiting
3
15
Europe
Baricitinib, Oliumiant
University of Erlangen-Nürnberg Medical School
Rheumatoid Arthritis, Bone Density, Finger Joints
10/21
10/21
NCT04890626: Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

Completed
3
356
Europe
Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA], Baricitinib + dexamethasone, Dexamethasone
Instituto de Investigación Hospital Universitario La Paz
SARS-CoV-2 Infection
07/23
07/23
NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

Withdrawn
3
382
RoW
Baricitinib, Janus kinase inhibitors, Dexamethasone, Steroids, Remdesivir, Anti-viral
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
COVID-19 Pneumonia
12/21
12/21
AMMURAVID, NCT04832880 / 2020-001854-23: Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the Trial)

Not yet recruiting
3
4000
Europe
Baricitinib Oral Tablet [Olumiant], Olumiant, Remdesivir, Veklury, Dexamethasone
ASST Fatebenefratelli Sacco, AIFA
Covid19
03/22
12/22
NCT05056558: Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

Not yet recruiting
3
480
RoW
Baricitinib, Baricent, Placebo, Given Orally
Incepta Pharmaceuticals Ltd
Covid19
04/22
09/22
BREEZE-AD-PEDS, NCT03952559 / 2018-000349-38: A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Active, not recruiting
3
516
Europe, Japan, RoW
Baricitinib, LY3009104, Placebo, Topical corticosteroid
Eli Lilly and Company, Incyte Corporation
Atopic Dermatitis
04/22
05/26
2022-000366-18: Efficacy and Tolerance of Baricitinib, a JAK inhibitor, in the treatment of refractory non-infectious uveitis Efficacité et Tolérance du Baricitinib, un inhibiteur de JAK, dans le traitement des uvéites non-infectieuses non-antérieures réfractaires

Not yet recruiting
3
33
Europe
Tablet, OLUMIANT
CHU de ROUEN, CHU de Rouen
Active non-anterior non-infectious uveitis, Active non-anterior non-infectious uveitis, Diseases [C] - Eye Diseases [C11]
 
 
NCT04088409 / 2019-000119-10: A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Active, not recruiting
3
30
Europe
Baricitinib, LY3009104, Adalimumab
Eli Lilly and Company
Uveitis
07/23
07/28
JAKUVEITE, NCT05651880: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Not yet recruiting
3
33
NA
Baricitinib 4 MG
University Hospital, Rouen
Active Non-anterior Non-infectious Uveitis
08/23
08/26
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
10/23
04/24
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
BardSSc, NCT06936215: Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Recruiting
3
24
RoW
tab baricitinib 4 mg daily, tab methotrexate 25 mg weekly with folic acid 5 mg weekly
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Diffuse Cutaneous Systemic Sclerosis
05/25
05/25
REVERSE-LC, NCT05858515: REVERSE-Long COVID-19 With Baricitinib Study

Withdrawn
3
550
US
Baricitinib 4 MG, Olumiant, Placebo
Vanderbilt University Medical Center, Emory University, University of California, San Francisco, University of Minnesota, Vanderbilt University, Yale University
Post-Acute COVID-19 Syndrome
12/27
12/29
COV-BARRIER, NCT05074420 / 2021-001338-21: A Study of Baricitinib (LY3009104) in Children With COVID-19

Recruiting
3
24
Europe, US, RoW
Baricitinib, LY3009104
Eli Lilly and Company, Eli Lilly and Company
Covid19, Corona Virus Infection
04/26
05/26
REVERSE-LC, NCT06631287: Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Recruiting
3
550
US
Baricitinib, OLUMIANT, Placebo
Wes Ely, National Institutes of Health (NIH), National Institute on Aging (NIA)
Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
11/26
07/27
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/27
08/29
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, anti-TNF therapy, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/26
12/26
TREAT-HAP, NCT05914584: "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Not yet recruiting
3
450
Europe
Baricitinib 4 MG
Nantes University Hospital
Hospital-acquired Pneumonia
08/25
12/25
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
04/26
05/26
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BIRD, NCT04972760: Baricitinib in Patients With Relapsing or naïve Dermatomyositis

Recruiting
3
62
Europe
Baricitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Dermatomyositis
02/26
02/26
PALETTE, NCT06381661: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial

Not yet recruiting
3
2000
NA
Tocilizumab, Baricitinib, Anakinra, Hydrocortisone, Hydrocortisone and fludrocortisone, Heparin, Low molecular weight heparin, Recombinant humanThrombomodulin( rhTM), Sivelestat, Fresh frozen plasma, Usual care
Assistance Publique - Hôpitaux de Paris
Sepsis
05/29
04/32
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
02/27
12/28
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Checkmark From BRAVE-AA1 trial for alopecia areata
Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata
Completed
2/3
784
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
02/21
01/25
NCT04517253 / 2025-000001-16: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Terminated
2/3
10
Japan
Baricitinib, LY3009104
Eli Lilly and Company, Eli Lilly and Company
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
10/21
11/24
NCT04891133 / 2021-000541-41 / ACTRN12619000823178: EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

Terminated
2/3
290
Europe, RoW
Baricitinib, Olumiant, Placebo
Oslo University Hospital, Institut National de la Santé Et de la Recherche Médicale, France, Epidemiological and Clinical Research Information Network
Stroke, Memory deficits
12/22
01/23
NCT05686746: Use of Baricitenib to Maintain of Remission

Recruiting
2/3
80
RoW
Baricitinib 4 MG, Baricitinib 2 MG, MMF
Assiut University
Lupus or SLE, Nephritis
06/23
08/23
NCT06475820: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Active, not recruiting
2/3
150
RoW
Baricitinib, Vedolizumab, Abatacept, Cyclophosphamide
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
07/24
04/27
NCT06768840: Vitiligo, New Treatment and Serum s100B

Recruiting
2/3
50
RoW
Baricitinib, oral mini pulse, Narrow Band UVB Treatment
South Valley University
Vitiligo, Generalized
08/25
10/25
2025-000001-16: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/​CANDLE, SAVI, and AGS

Not yet recruiting
2/3
10
Japan
Olumiant, LY3009104, Film-coated tablet, Oral suspension, Olumiant
Eli Lilly and Company, Eli Lilly and Company
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Syndrome, Autoinflammatory diseases, Diseases [C] - Immune System Diseases [C20]
 
 
MYOJAK, NCT04208464 / 2019-003868-42: JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Completed
2a
15
Europe
Baricitinib
University of Manchester, Eli Lilly and Company, Clinical Trials Unit, Manchester, Karolinska Institutet
Idiopathic Inflammatory Myopathies
09/23
09/23
2015-003424-31: Treatment of autoinflammatory diseases

Not yet recruiting
2
60
Europe
Baricitinib, LY3009104, Coated tablet
Eli Lilly and Company, Eli Lilly and Company
CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome, CANDLE, SAVI, JDM, AGS, Diseases [C] - Immune System Diseases [C20]
 
 
2018-002655-14: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR study)

Not yet recruiting
2
34
Europe
OLUMIANT, Tablet, baricitinib
CHRU BREST
polymyalgia rheumatica, Inflammatory disease in the elderly, Diseases [C] - Immune System Diseases [C20]
 
 
2019-003868-42: A trial of the drug Baricitinib in the treatment of patients with muscle inflammatory conditions.

Not yet recruiting
2
25
Europe
Olumiant, Tablet, Olumiant
University of Manchester, Eli Lilly and Company
Idiopathic Inflammatory Myopathy (IIM), Inflammation of muscle tissue which can lead to profound weakness, fatigue and disability, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2020-005079-12: Efficacy and tolerability of the combination of baricitinib (4 mg) and phototherapy compared to phototherapy in adults with vitiligo-progressive disease Efficacité et tolérance de l’association du baricitinib (4 mg) et de la photothérapie par rapport à la photothérapie chez les adultes atteints de vitiligo progressif

Not yet recruiting
2
48
Europe
Baricitinib, LY3009104, Film-coated tablet, Olumiant
Centre Hospitalier Universitaire de Bordeaux, LILLY France
progressive vitiligo vitiligo progressif, progressive vitiligo vitiligo progressif, Diseases [C] - Immune System Diseases [C20]
 
 
Covid-19HUF, NCT04346147 / 2020-001321-31: Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Active, not recruiting
2
168
Europe
Imatinib tablets, Arm A, Baricitinib Oral Tablet, Arm B, Supportive tratment, Best care
Hospital Universitario de Fuenlabrada, Centro Nacional de Investigaciones Oncologicas CARLOS III
COVID-19 Pneumonia
06/21
09/21
ACTRN12620000239965: Effect of Baricitinib on Insulin Production in Type 1 Diabetes

Active, not recruiting
2
91
 
St Vincent’s Institute of Medical Research, Juvenile Diabetes Research Foundation (JDRF) International, JDRF Australia
Type 1 Diabetes Mellitus
 
 
2021-006562-20: Inhibition of JAK Enzymes in early stage Joint inflammation Hemmung der JAK-Enzyme bei frühen Formen von Gelenkentzündung

Not yet recruiting
2
20
Europe
Baricitinib blinded, Film-coated tablet, Olumiant 2 mg/4 mg Filmtabletten
Universitätsklinikum Erlangen, Lilly Deutschland GmbH
Preclinical Phase of rheumatoid arthritis Vorstadium der rheumatoiden Arthritis, Preclinical Phase of rheumatoid arthritis Vorstadium der rheumatoiden Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
BANDIT, NCT04774224: Baricitinib in New-onset Type 1 Diabetes

Completed
2
91
RoW
Baricitinib, Placebo
St Vincent's Institute of Medical Research, Juvenile Diabetes Research Foundation Australia, Juvenile Diabetes Research Foundation
Type 1 Diabetes
01/23
05/24
NCT05400889: Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Recruiting
2
10
RoW
tofacitinib, Baricitinib
Peking University People's Hospital
Idiopathic Inflammatory Myopathies
03/23
06/23
NCT05361109: Baricitinib for Cutaneous Dermatomyositis

Withdrawn
2
10
US
Baricitinib, Olumiant
University of Washington
Dermatomyositis
03/23
03/23
NCT06662721: Baricitinib for Refractory Takayasu Arteritis

Completed
2
10
RoW
Baricitinib 4 MG
Liu Tian
Takayasu Arteritis
12/23
06/24
BARVIT, NCT04822584: Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Completed
2
49
Europe
Baricitinib Oral Product, Placebo
University Hospital, Bordeaux
Vitiligo
04/23
04/23
NCT05188521: Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Completed
2
12
US
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Aaron R. Mangold
Cutaneous Lichen Planus
05/23
05/23
BACHELOR, NCT04027101: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica

Completed
2
34
Europe
Baricitinib, Placebos
University Hospital, Brest, Eli Lilly and Company
Polymyalgia Rheumatic (PMR)
08/23
08/23
BAITP, NCT05446831: Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
35
RoW
Baricitinib
Peking University People's Hospital
ITP, Immune Thrombocytopenia
06/23
12/23
NCT05263505: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Terminated
2
2
US
Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
Washington University School of Medicine, Eli Lilly and Company
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
09/23
09/23
NCT03755466: Examination of Efficacy and Safety of Baricitinib in RA Patients

Recruiting
2
90
Japan
"Baricitinib", "olumiant®", "Biologics", Tofacitinib 5 MG [Xeljanz]
Shinshu University
Rheumatoid Arthritis
11/23
11/25
NCT06158113: Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

Recruiting
2
10
US
Baricitinib 4 milligram Oral Tablet, Olumiant
University of North Carolina, Chapel Hill, Eli Lilly and Company
Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
03/25
03/25
NCT06114407: Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Recruiting
2
184
RoW
Baricitinib 2mg, Baritinib 2 mg, Tofacitinib 5 mg, Tofacent 5 mg
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Healthcare Pharmaceuticals
Spondyloarthritis, Axial
06/24
12/24
NCT04321993: Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

Active, not recruiting
2
363
Canada
Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor), Remdesivir (antiviral), Tocilizumab (interleukin 6 inhibitor)
Lisa Barrett, Nova Scotia Health Authority, Dalhousie University
COVID-19
04/24
04/24
NCT05932524: Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia

Recruiting
2
132
RoW
Baricitinib 2 MG, Olumiant, Dexamethasone, HD-DXM
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
06/24
06/25
ChiCTR2100048030: Efficacy and Safety of Baricitinib in refractory Non-infectious Uveitis

Recruiting
2
30
 
Baricitinib
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Academy Foundation of Tongji Hospital
Non-infectious Uveitis
 
 
NCT05016297: Efficacy and Safety of Baricitinib in Sjogren's Syndrome

Completed
2
90
RoW
Baricitinib, Hydroxychloroquine
Peking Union Medical College Hospital, Eli Lilly and Company
Sjogren's Syndrome
08/24
11/24
BLISS, NCT06439615: Baricitinib for the Lung Injury Following Spontaneous SAH

Not yet recruiting
2
100
NA
Baricitinib 4 MG, JAK Inhibitor, Standard treatment
Tang-Du Hospital
Spontaneous Subarachnoid Hemorrhage
12/26
06/27
JAKIH, NCT06490757: A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

Not yet recruiting
2
25
NA
Baricitinib, fluorodésoxyglucose (18F)- Positron Emission Tomography (PET)
Assistance Publique - Hôpitaux de Paris
Inflammatory Hepatocellular Adenoma
09/28
09/28
NCT05852847: Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
216
RoW
Baricitinib 2 MG [Olumiant], Olumiant, Danazol
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
11/24
05/25
NCT06849908: Baricitinib in the Treatment of Intestinal Behçet's Syndrome

Recruiting
2
56
RoW
Baricitinib, Olumiant®, Adalimumab, Humira®
Peking Union Medical College Hospital
Behcet Syndrome, Intestinal Type
06/27
06/28
NCT04901325: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Completed
2
5
US
Baricitinib, Olumiant
Oregon Health and Science University
Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
01/25
05/25
BAPTIST, NCT06768294: Baricitinib in CPPD - the Study

Not yet recruiting
2
32
Europe
Baricitinib 4 MG Oral Tablet, Methylprednisolone (Corticosteroid), Colchicine 1 MG Oral Tablet, Hydroxychloroquine 200 mg, Methotrexate + Folic Acid
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
06/26
01/27
BRIGHT, NCT06737705: Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage

Recruiting
2
100
RoW
Baritinib
De-zhi Kang, Fujian Medical University, Tianjin Medical University General Hospital
Intracerebral Hemorrhage, Acute Lung Injury(ALI)
12/25
03/26
MQ7422, NCT06797310: Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study

Not yet recruiting
2
30
RoW
Baricitinib
National Taiwan University Hospital, Eli Lilly and Company
Alopecia Areata
12/25
12/26
NCT06868381: A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Not yet recruiting
2
10
US
Baricitinib (LY3009104) 4 mg
Stanford University, Eli Lilly and Company
Cardiac Sarcoidosis
01/28
04/28
NCT06923072: Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

Recruiting
2
12
US
Baricitinib
National Heart, Lung, and Blood Institute (NHLBI)
Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
12/30
12/30
NCT03921554: JAK Inhibitor Treatment in AGS

Completed
2
54
US
Baricitinib, Olumiant
Adeline Vanderver, MD, Eli Lilly and Company
Aicardi Goutieres Syndrome
01/24
03/24
WP3, NCT05897372: Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

Terminated
2
1
Europe
ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Iain Bressendorff
Diabetic Kidney Disease
09/24
09/24
NCT06065046: Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Not yet recruiting
2
100
RoW
Baricitinib 4 MG, Baricitinib, Standard treatment, Blank control
Tang-Du Hospital
Traumatic Brain Injury
07/25
12/25
NCT05852171: Baricitinib in Idiopathic Granulomatous Mastitis

Active, not recruiting
2
20
RoW
Baricitinib, Olumiant, Baricinix
First Affiliated Hospital of Zhejiang University
Mastitis Chronic, Idiopathic Granulomatous Mastitis
04/25
12/25
 

Download Options